All In Biotech

Investigational drug · Phase 3

Crenolanib

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Newly Diagnosed FLT3 Mutated AML, Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations.

Phase 3

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

22

Any phase or sponsor naming "Crenolanib"

First trial start

2018

Aug 15, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Crenolanib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Newly Diagnosed FLT3 Mutated AML
  • Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Crenolanib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 127 on PubMed

Also in development for Newly Diagnosed FLT3 Mutated AML

  • DuanorubicinPhase 31 trial

    Arog Pharmaceuticals, Inc. · Newly Diagnosed FLT3 Mutated AML

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.